Tactile Systems Technology, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87357P1003
USD
26.81
0.66 (2.52%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

329.96 k

Shareholding (Mar 2025)

FII

11.19%

Held by 71 FIIs

DII

51.9%

Held by 40 DIIs

Promoter

0.00%

How big is Tactile Systems Technology, Inc.?

22-Jun-2025

As of Jun 18, Tactile Systems Technology, Inc. has a market capitalization of 228.07 million and reported net sales of 293.16 million and a net profit of 16.21 million over the latest four quarters.

As of Jun 18, Tactile Systems Technology, Inc. has a market capitalization of 228.07 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 293.16 million, while the sum of net profit for the same period is 16.21 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 216.60 million, and total assets are reported at 303.34 million.

Read More

What does Tactile Systems Technology, Inc. do?

22-Jun-2025

Tactile Systems Technology, Inc. is a medical technology company that develops home treatment devices for chronic diseases, classified as a micro-cap with a market cap of $228.07 million. As of March 2025, it reported net sales of $61 million and a net profit of -$3 million.

Overview: <BR>Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 61 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 228.07 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.27 <BR>Return on Equity: 7.88% <BR>Price to Book: 1.11 <BR><BR>Contact Details: <BR>Address: 1331 Tyler St NE Ste 200, MINNEAPOLIS MN : 55413-1638 <BR>Tel: ['1 612 3555100', '1 443 2130500'] <BR>Fax: 1 612 3555101 <BR>Website: https://www.tactilemedical.com/

Read More

Should I buy, sell or hold Tactile Systems Technology, Inc.?

22-Jun-2025

Who are in the management team of Tactile Systems Technology, Inc.?

22-Jun-2025

As of March 2022, Tactile Systems Technology, Inc.'s management team includes Peter Soderberg (Independent Chairman), Daniel Reuvers (CEO), Sheri Dodd, Deepti Jain, William Burke, Raymond Huggenberger, and Richard Nigon (all Independent Directors). They oversee the company's operations and strategic direction.

As of March 2022, the management team of Tactile Systems Technology, Inc. includes the following individuals:<BR><BR>- Mr. Peter Soderberg, Independent Chairman of the Board<BR>- Mr. Daniel Reuvers, President, Chief Executive Officer, Director<BR>- Ms. Sheri Dodd, Director<BR>- Ms. Deepti Jain, Director<BR>- Mr. William Burke, Independent Director<BR>- Mr. Raymond Huggenberger, Independent Director<BR>- Mr. Richard Nigon, Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Read More

Is Tactile Systems Technology, Inc. technically bullish or bearish?

20-Sep-2025

As of July 24, 2025, Tactile Systems Technology, Inc. shows a mildly bearish trend with mixed technical signals, including a bullish weekly MACD and bearish monthly MACD, while outperforming the S&P 500 recently but down 17.75% year-to-date.

As of 24 July 2025, the technical trend for Tactile Systems Technology, Inc. has changed from bearish to mildly bearish. The weekly MACD is bullish, while the monthly MACD is bearish, indicating mixed signals. The Bollinger Bands are bullish on both weekly and monthly time frames, suggesting potential upward movement. However, the daily moving averages are mildly bearish, and the KST shows a bullish weekly trend but a bearish monthly trend. Dow Theory indicates a mildly bullish stance on both weekly and monthly periods, while the OBV is mildly bearish weekly but mildly bullish monthly.<BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 2.77% and 12.00% respectively, compared to 1.05% and 2.33% for the index. However, year-to-date, the stock is down 17.75%, while the S&P 500 has gained 12.22%. Overall, the current technical stance is mildly bearish, with key indicators showing mixed signals.

Read More

Is Tactile Systems Technology, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Tactile Systems Technology, Inc. is considered overvalued with a fair valuation grade, reflected by its P/E ratio of 14 and poor year-to-date performance of -15.18% compared to the S&P 500's 13.30%.

As of 17 October 2025, Tactile Systems Technology, Inc. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics, with a P/E ratio of 14, a Price to Book Value of 1.14, and an EV to EBITDA of 6.49. In comparison, CareDx, Inc. is rated very attractive with a significantly lower P/E ratio of -27.91, while Organogenesis Holdings, Inc. is considered risky with a P/E ratio of 608.59, highlighting the relative valuation challenges Tactile faces.<BR><BR>Despite a recent positive performance with a 1-week return of 2.18% compared to the S&P 500's 1.70%, the year-to-date return of -15.18% against the S&P 500's 13.30% suggests that Tactile is struggling to keep pace with broader market trends. Overall, the combination of its valuation ratios and peer comparisons indicates that Tactile Systems Technology, Inc. is currently overvalued.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company has a low Debt to Equity ratio (avg) at times

 
2

Flat results in Jun 25

3

With ROE of 7.88%, it has a attractive valuation with a 1.14 Price to Book Value

4

High Institutional Holdings at 100%

5

Consistent Returns over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 300 Million (Micro Cap)

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.28

stock-summary
Return on Equity

7.75%

stock-summary
Price to Book

1.54

Revenue and Profits:
Net Sales:
79 Million
(Quarterly Results - Jun 2025)
Net Profit:
3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
102.49%
0%
102.49%
6 Months
160.8%
0%
160.8%
1 Year
41.93%
0%
41.93%
2 Years
94.77%
0%
94.77%
3 Years
185.52%
0%
185.52%
4 Years
41.11%
0%
41.11%
5 Years
-34.16%
0%
-34.16%

Tactile Systems Technology, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
10.01%
EBIT Growth (5y)
80.95%
EBIT to Interest (avg)
3.61
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
1.23
Tax Ratio
27.14%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
5.13%
ROE (avg)
4.37%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
1.14
EV to EBIT
8.65
EV to EBITDA
6.49
EV to Capital Employed
1.18
EV to Sales
0.61
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
13.69%
ROE (Latest)
7.88%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 71 Schemes (36.91%)

Foreign Institutions

Held by 71 Foreign Institutions (11.19%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 7.79% vs 7.17% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -25.58% vs 4,400.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "78.90",
          "val2": "73.20",
          "chgp": "7.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.70",
          "val2": "7.60",
          "chgp": "-25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.20",
          "val2": "4.30",
          "chgp": "-25.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "51.70%",
          "val2": "79.90%",
          "chgp": "-2.82%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.78% vs 11.18% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -40.35% vs 259.22% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "293.00",
          "val2": "274.40",
          "chgp": "6.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "29.00",
          "val2": "22.10",
          "chgp": "31.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "2.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "17.00",
          "val2": "28.50",
          "chgp": "-40.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "75.70%",
          "val2": "56.70%",
          "chgp": "1.90%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
78.90
73.20
7.79%
Operating Profit (PBDIT) excl Other Income
5.70
7.60
-25.00%
Interest
0.40
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
3.20
4.30
-25.58%
Operating Profit Margin (Excl OI)
51.70%
79.90%
-2.82%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 7.79% vs 7.17% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -25.58% vs 4,400.00% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
293.00
274.40
6.78%
Operating Profit (PBDIT) excl Other Income
29.00
22.10
31.22%
Interest
2.10
0.00
Exceptional Items
0.00
2.50
-100.00%
Consolidate Net Profit
17.00
28.50
-40.35%
Operating Profit Margin (Excl OI)
75.70%
56.70%
1.90%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 6.78% vs 11.18% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -40.35% vs 259.22% in Dec 2023

stock-summaryCompany CV
About Tactile Systems Technology, Inc. stock-summary
stock-summary
Tactile Systems Technology, Inc.
Pharmaceuticals & Biotechnology
Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home. The Company is a manufacturer and distributor of the Flexitouch and Entre Systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition that is often an unintended consequence of cancer treatment, and the ACTitouch System, a medical device used to treat venous leg ulcers and chronic venous insufficiency. Its products deliver long-term treatment of chronic diseases. The Company provides its products for use in the home and sells them through vascular, wound and lymphedema clinics throughout the United States. The Company offers a platform to deliver at-home healthcare solutions throughout the United States. Its initial area of therapeutic focus is vascular disease, with a focus on advancing the care in treating lymphedema and chronic venous insufficiency.
Company Coordinates stock-summary
Company Details
1331 Tyler St NE Ste 200 , MINNEAPOLIS MN : 55413-1638
stock-summary
Tel: 1 612 35551001 443 2130500
stock-summary
Registrar Details